Youdim, Moussa B.H.
Moussa B. H. Youdim Israeli-Iranian neuroscientist
Youdim, Moussa B.H. 1941-
יודעים, מוסא
Youdim, Moussa B. H., 1940-
VIAF ID: 94374218 (Personal)
Permalink: http://viaf.org/viaf/94374218
Preferred Forms
- 100 0 _ ‡a Moussa B. H. Youdim ‡c Israeli-Iranian neuroscientist
-
- 100 1 _ ‡a Youdim, Moussa B. H.
- 100 1 0 ‡a Youdim, Moussa B. H.
-
-
-
-
-
- 100 1 _ ‡a Youdim, Moussa B. H., ‡d 1941-....
-
-
-
- 100 1 _ ‡a Youdim, Moussa B.H. ‡d 1941-
- 100 1 _ ‡a Youdim, Moussa B.H. ‡d 1941-
-
4xx's: Alternate Name Forms (24)
Works
Title | Sources |
---|---|
Amine oxidases and their impact on neurobiology : proceedings of the 4th International Amine Oxidases Workshop, Würzburg, Federal Republic of Germany, July 7-10, 1990 | |
Aromatic amino acid hydroxylases and mental disease | |
Biochemical and pharmacological aspects of depression | |
Brain iron : neurochemical and behavioural aspects | |
The Cheese effects and selective MAO-A inhibitors, c1988: | |
Cooperative coordinated behavior in laboratory rats : comparison of coordinated cooperation with non-coordinated and individual behaviors : involvement of the monoaminergic neurotransmitters systems, 2002: | |
Degenerative diseases of the nervous system | |
Enzymes and neurotransmitters in mental disease : based on a symposium held at the Technion Faculty of Medicine, Haifa, Israel, August 28-30, 1979 | |
Essays in neurochemistry and neuropharmacology | |
Iron in central nervous system disorders | |
Neurodegeneration and neuroprotection in parkinson's disease | |
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis | |
The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity | |
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease | |
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline | |
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties | |
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities | |
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. | |
Neurotransmitter actions and interactions : proceedings of a satellite symposium of the 12th International Society for Neurochemistry Meeting, Algarve, Portugal, April 29-30, 1989 | |
Nigericin-induced impairment of autophagic flux in neuronal cells is inhibited by overexpression of Bak. | |
Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein | |
The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats | |
A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities | |
A Novel Iron Chelator-Radical Scavenger Ameliorates Motor Dysfunction and Improves Life Span and Mitochondrial Biogenesis in SOD1G93A ALS Mice. | |
The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. | |
The novel multi-target iron chelator, M30 modulates HIF-1α-related glycolytic genes and insulin signaling pathway in the frontal cortex of APP/PS1 Alzheimer's disease mice. | |
The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage | |
The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models | |
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway | |
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage | |
Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway | |
Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death | |
The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. | |
Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators | |
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators | |
Proceedings from the "Third International Conference on Mechanism of Action of Nutraceuticals" | |
Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity | |
A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist | |
Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently | |
Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation | |
Psychiatric, nonmotor aspects of Parkinson's disease | |
Purification of mitochondrial monoamine oxidase and its properties. | |
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine | |
Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo | |
The relevance of iron in the pathogenesis of Parkinson's disease | |
Reversible and selective inhibitors of monoamine oxidase type A : new findings | |
The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions | |
Role of iron in neurodegenerative disorders | |
A screening system of prodrugs selective for MAO-A or MAO-B. | |
Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease | |
SSRI augmentation of antipsychotic alters expression of GABA | |
Striatal dopa and glucose metabolism in PD patients with freezing of gait. | |
Structure and function of monoamine enzymes : proceedings of a conference held in Steamboat Springs, Colorado, March 10-13, 1977 | |
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators | |
Targeting SKP1, an ubiquitin E3 ligase component found decreased in sporadic Parkinson's disease | |
Theodore Lionel Sourkes obituary. | |
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease | |
Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration | |
Tribute to professor Toshiharu Nagatsu. | |
TVP1022: A Novel Cardioprotective Drug Attenuates Left Ventricular Remodeling After Ischemia/Reperfusion in Pigs. | |
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. | |
TVP1022 Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure |